GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Exercise Prices of Executive Options

Below are all options held by executive officers
with an exercise price <=$2/share. (Source: SEC
Form DEF14a for the 2007 annual meeting and
subsequent Form-4 filings.) Not shown below are
options held by directors other than Dr. Cox and
options held by Dick Scotland, SVP Regulatory.
(these are not included in the DEF14a filing).

Under the change-of-control provisions in the employment
contracts between GTC and the executive officers, all
options vest immediately in the event of a buyout.

 
 Geoffrey Cox, CEO           75K @0.63 
                             90K @1.03 
                             88K @1.04 
                             22K @1.18 
                            125K @1.45 
                             75K @1.71 
                             15K @1.890 
                            ==== 
                            490K 
   
   
 John Green, CFO             25K @0.63 
                             35K @1.03 
                             23K @1.04 
                             22K @1.18 
                             50K @1.45 
                             39K @1.71 
                            ==== 
                            194K 
   
   
 Harry Meade, SVP Research   25K @0.63 
                             50K @1.03 
                             45K @1.04 
                             45K @1.45 
                             39K @1.71 
                            ==== 
                            179K 
   
   
 Dan Woloshen, Gen. Counsel  35K @0.63 
                             25K @1.03 
                             35K @1.04 
                             45K @1.45 
                             27K @1.71 
                            ==== 
                            147K